Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy

BALLERINI, MARÍA GABRIELA; BRASLAVSKY, DÉBORA; SCAGLIA, PAULA ALEJANDRA; KESELMAN, ANA; RODRÍGUEZ, MARÍA EUGENIA; MARTÍNEZ, ALICIA; FREIRE, ANALÍA VERÓNICA; DOMENÉ, HORACIO MARIO; JASPER, HÉCTOR GUILLERMO; BERGADÁ, IGNACIO; ROPELATO, MARÍA GABRIELA

Hormone Research in Paediatrics

Karger

Lugar: Basilea; Año: 2017 vol. 88 p. 354 - 363

1663-2818

Objective: To investigate the occurrence of abnormally elevatedvalues of biomarkers of growth hormone (GH) actionin short children on recombinant human GH (rhGH) therapy.Methods: Sixty-three prepubertal short children were examined:31 with GH deficiency (GHD), 25 small for gestationalage (SGA), and 9 with Turner syndrome (TS). The main outcomeswere the following: standard deviation score (SDS)values of IGF-I, IGFBP-3, and IGF-I/IGFBP-3 molar ratio before,at the 1st and at the 2nd year on rhGH and Δheight (Ht)-SDSto evaluate GH treatment efficacy (adequate 1st-year ΔHtSDS: >0.4 SDS for GHD and >0.3 SDS for non-GHD). Results:Seventy-eight percent of GHD, 78% of SGA and 55% of TSchildren had adequate 1st-year ΔHt SDS. In GHD, 88% ofIGF-I SDS and IGFBP-3 SDS that were ≤?2.0 SDS at baselinenormalized on treatment. Abnormal IGF-I values >+2.0 SDSwere observed in 52% of SGA and in 55% of TS patients onrhGH. Within each group, the IGF-I/IGFBP-3 molar ratio increasedsignificantly from pretreatment and throughouttherapy, remaining within normal range for most patients.ΔIGF-I/IGFBP-3 molar ratio SDS were significantly higher inchildren with an adequate response (p < 0.01). Conclusion:Non-GHD groups presented markedly elevated concentrationsof GH biomarkers on rhGH and normal IGF-I/IGFBP-3molar ratio in most patients. Since there is a lack of consensusregarding the molar ratio usefulness, we think that interventionstowards a more physiological IGF-I serum profileshould be implemented.